LadRx Plans NDA Submission for Aldoxorubicin Under 505(b)(2) Pathway
LadRx Corporation announces its intention to seek marketing approval for aldoxorubicin, a cancer therapeutic, under the FDA's Section 505(b)(2), potentially accelerating its path to market without the need for additional human clinical studies.
© Copyright 2025. All Rights Reserved by MedPath